By the end of 2024, the total number of medical and health institutions nationwide reached 1,093,551, an increase of 22,766 compared to the previous year.

Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

CareDx said it has filed a patent infringement suit against Natera in the U.S. District Court for Delaware. The Brisbane, CA-based company said it is asserting U.S. Patent Nos. 9,845,497 and 8,703,652, were exclusively licensed to itfrom Sta

Guardant Health is expanding its early cancer detection efforts through a new acquisition. The Redwood City, CA-based firm is set to pick up Bellwether Bio, a private company focused on improving oncology patient care through pioneering rese

Bacillusbacteria detection devices were previously unclassified, known as preamendment devices, since they were in commercial distribution prior to May 28, 1976, when the Medical Device Amendments to the Federal Food, Drug, and Cosmetic Act

PredictImmune announced recently that it has entered a commercial agreement with Addenbrookes Hospital part of Cambridge University Hospitals National Health Service Foundation Trust to provide the companys PredictSure IBD prognostic assay

A new study by Veracyte and collaborators demonstrates that the companys Envisia genomic test can improve the diagnosis of patients being evaluated for interstitial lung disease. The study, published this week in Lancet Respiratory Medicine

Genomic Health reported recently that its fourth quarter revenues rose 22 percent year over year, beating the consensus Wall Street estimate of $101.5 million. For the three months ended Dec. 31, 2018, the companys total revenues were $104.6

Recently, the Wall Street Journal reported that Swiss biopharmaceutical company Roche is acquiring US technology company Spark Theraputics, which may be announced on Monday. The acquisition will value Sparks nearly $5 billion, while the Nasd

Danaher Corporation announced that it has entered into a definitive agreement with General Electric to acquire GE Life Sciences GE Biopharma business with a cash purchase price of approximately $21.4 billion. Given the expected tax benefits

Icon, an international drug-development and commercialization services firm, has acquired MolecularMD for an undisclosed amount, the companies said recently. MolecularMD, based in Portland, Oregon, is a molecular diagnostic laboratory that s

Exact Sciences reported after the close of the market recently that its fourth quarter revenues rose 64 percent year over year, thanks to a 66 percent increase in the number of completed Cologuard colorectal cancer tests during the quarter.